[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fAkDK9tY07pVN5WkLPnBqgwWBoyRSaIMALBCL79vpoqA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":59,"rows":66},"Grifols Therapeutics LLC",[4],47,false,5,18,4465,4,0,[14,17,20,22,24,27,29,32],{"name":15,"count":16},"Primary Immunodeficiency",6,{"name":18,"count":19},"COVID-19",3,{"name":21,"count":19},"Alpha 1-Antitrypsin Deficiency",{"name":23,"count":19},"Alpha1-Antitrypsin Deficiency",{"name":25,"count":26},"Cystic Fibrosis",2,{"name":28,"count":26},"Immunologic Deficiency Syndrome",{"name":30,"count":31},"Acute Ischemic Stroke",1,{"name":33,"count":31},"Emphysema",[35,40,45,50,55],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05645107","A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma","2026-05","Xembify",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT01983241","Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)","2026-08","Alpha-1 MP",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT07555483","A Non-inferiority Pharmacokinetic and Safety\u002FTolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)","2027-09-30","Alpha-1 15%",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT07540221","A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy","2027-12-31","Gamunex-C",{"nctId":56,"briefTitle":57,"date":58,"intervention":44},"NCT02796937","Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency","2028-09",[60,61,62,63,64,65],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[67,125,159,208,238,282,308,334,352,377,435,480,511,536,554,572,599,617,643,661,679,697,722,747,772,790,808,826,860,888,910,938,964,990,1008,1035,1053,1077,1095,1119,1142,1160,1184,1208,1234,1264,1282,1300,1318,1336,1354,1372],{"intervention":44,"totalTrials":8,"cells":68},{"EARLY_PHASE1":69,"PHASE1":71,"PHASE2":73,"PHASE3":91,"PHASE4":121,"NA":123},{"trials":70,"activeCount":12},[],{"trials":72,"activeCount":12},[],{"trials":74,"activeCount":12},[75,84],{"nctId":76,"briefTitle":77,"status":78,"phases":79,"primaryCompletion":80,"completion":80,"start":81,"enrollment":11,"conditions":82,"interventions":83},"NCT02870309","Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency","COMPLETED",[61,62],"2017-03-15","2016-07-29",[23],[44],{"nctId":85,"briefTitle":86,"status":78,"phases":87,"primaryCompletion":88,"completion":88,"start":81,"enrollment":11,"conditions":89,"interventions":90},"NCT02870348","Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)",[61,62],"2021-02-16",[23],[44],{"trials":92,"activeCount":26,"soonestReadout":43},[93,102,112],{"nctId":41,"briefTitle":42,"status":94,"phases":95,"primaryCompletion":43,"completion":96,"start":97,"enrollment":98,"conditions":99,"interventions":101},"ACTIVE_NOT_RECRUITING",[63],"2027-01","2013-11",345,[100],"Pulmonary Emphysema in Alpha-1 PI Deficiency",[44],{"nctId":103,"briefTitle":104,"status":78,"phases":105,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":110},"NCT00295061","Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults",[63],"2007-02","2006-05",24,[21],[44,111],"alpha-1 proteinase inhibitor",{"nctId":56,"briefTitle":57,"status":113,"phases":114,"primaryCompletion":58,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":120},"ENROLLING_BY_INVITATION",[63],"2029-02","2016-07",290,[119],"Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency",[44],{"trials":122,"activeCount":12},[],{"trials":124,"activeCount":12},[],{"intervention":39,"totalTrials":26,"cells":126},{"EARLY_PHASE1":127,"PHASE1":129,"PHASE2":131,"PHASE3":133,"PHASE4":155,"NA":157},{"trials":128,"activeCount":12},[],{"trials":130,"activeCount":12},[],{"trials":132,"activeCount":12},[],{"trials":134,"activeCount":26,"soonestReadout":38},[135,143],{"nctId":51,"briefTitle":52,"status":136,"phases":137,"primaryCompletion":53,"completion":53,"start":138,"enrollment":139,"conditions":140,"interventions":142},"RECRUITING",[63],"2026-04-02",40,[141],"CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)",[54,39],{"nctId":36,"briefTitle":37,"status":136,"phases":144,"primaryCompletion":38,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":154},[63],"2026-06","2022-12-26",386,[149,150,151,152,153],"Hypogammaglobulinemia","Bacterial Infections","B-cell Chronic Lymphocytic Leukemia","Multiple Myleoma","Non-Hodgkin Lymphoma",[39],{"trials":156,"activeCount":12},[],{"trials":158,"activeCount":12},[],{"intervention":160,"totalTrials":11,"cells":161},"GAMUNEX-C",{"EARLY_PHASE1":162,"PHASE1":164,"PHASE2":166,"PHASE3":179,"PHASE4":195,"NA":206},{"trials":163,"activeCount":12},[],{"trials":165,"activeCount":12},[],{"trials":167,"activeCount":12},[168],{"nctId":169,"briefTitle":170,"status":78,"phases":171,"primaryCompletion":172,"completion":173,"start":174,"enrollment":175,"conditions":176,"interventions":177},"NCT04480424","Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)",[62],"2021-08-25","2021-10-25","2020-09-17",100,[18],[160,178],"Standard Medical Treatment",{"trials":180,"activeCount":31,"soonestReadout":53},[181,185],{"nctId":51,"briefTitle":52,"status":136,"phases":182,"primaryCompletion":53,"completion":53,"start":138,"enrollment":139,"conditions":183,"interventions":184},[63],[141],[54,39],{"nctId":186,"briefTitle":187,"status":78,"phases":188,"primaryCompletion":189,"completion":189,"start":190,"enrollment":191,"conditions":192,"interventions":193},"NCT04561115","A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency",[63],"2022-03-28","2020-09-02",33,[15],[54,194],"IVIG-PEG",{"trials":196,"activeCount":12},[197],{"nctId":198,"briefTitle":199,"status":78,"phases":200,"primaryCompletion":201,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":205},"NCT01465958","Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency",[64],"2013-10","2011-11",12,[15],[160,160],{"trials":207,"activeCount":12},[],{"intervention":49,"totalTrials":26,"cells":209},{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":226,"PHASE4":234,"NA":236},{"trials":211,"activeCount":12},[],{"trials":213,"activeCount":12},[],{"trials":215,"activeCount":12},[216],{"nctId":217,"briefTitle":218,"status":78,"phases":219,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":224},"NCT04722887","A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency",[61,62],"2025-08-01","2021-08-13",17,[23],[49,225],"Liquid Alpha1-Proteinase Inhibitor",{"trials":227,"activeCount":31,"soonestReadout":48},[228],{"nctId":46,"briefTitle":47,"status":136,"phases":229,"primaryCompletion":48,"completion":48,"start":230,"enrollment":139,"conditions":231,"interventions":233},[63],"2026-05-05",[232],"Alpha 1 Antitrypsin Deficiency",[49],{"trials":235,"activeCount":12},[],{"trials":237,"activeCount":12},[],{"intervention":239,"totalTrials":19,"cells":240},"IGSC 20%",{"EARLY_PHASE1":241,"PHASE1":243,"PHASE2":245,"PHASE3":247,"PHASE4":269,"NA":280},{"trials":242,"activeCount":12},[],{"trials":244,"activeCount":12},[],{"trials":246,"activeCount":12},[],{"trials":248,"activeCount":12},[249,260],{"nctId":250,"briefTitle":251,"status":78,"phases":252,"primaryCompletion":253,"completion":254,"start":255,"enrollment":256,"conditions":257,"interventions":258},"NCT02604810","Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency",[63],"2017-09","2017-12","2016-01",53,[15],[259,239],"IGIV-C 10%",{"nctId":261,"briefTitle":262,"status":78,"phases":263,"primaryCompletion":264,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":268},"NCT02806986","Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency",[63],"2019-05-15","2016-06",61,[15],[239],{"trials":270,"activeCount":12},[271],{"nctId":272,"briefTitle":273,"status":78,"phases":274,"primaryCompletion":275,"completion":276,"start":277,"enrollment":191,"conditions":278,"interventions":279},"NCT04566692","A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading\u002FMaintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency",[64],"2022-07-18","2022-07-25","2020-11-24",[15],[239],{"trials":281,"activeCount":12},[],{"intervention":283,"totalTrials":31,"cells":284},"Immune Globulin",{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":289,"PHASE3":291,"PHASE4":293,"NA":306},{"trials":286,"activeCount":12},[],{"trials":288,"activeCount":12},[],{"trials":290,"activeCount":12},[],{"trials":292,"activeCount":12},[],{"trials":294,"activeCount":12},[295],{"nctId":296,"briefTitle":297,"status":78,"phases":298,"primaryCompletion":299,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":305},"NCT03351933","Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)",[64],"2018-04-27","2018-07-19","2017-10-31",28,[304],"Anti-Hepatitis A Antibody Levels in Heathy Subjects",[283],{"trials":307,"activeCount":12},[],{"intervention":309,"totalTrials":31,"cells":310},"Tetanus Immune Globulin",{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":319,"NA":332},{"trials":312,"activeCount":12},[],{"trials":314,"activeCount":12},[],{"trials":316,"activeCount":12},[],{"trials":318,"activeCount":12},[],{"trials":320,"activeCount":12},[321],{"nctId":322,"briefTitle":323,"status":324,"phases":325,"primaryCompletion":326,"completion":326,"start":327,"enrollment":16,"conditions":328,"interventions":330},"NCT00437671","Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels","TERMINATED",[64],"2007-09","2007-03",[329],"Tetanus",[309,331],"Diphtheria-Tetanus Toxoids Adsorbed",{"trials":333,"activeCount":12},[],{"intervention":331,"totalTrials":31,"cells":335},{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":340,"PHASE3":342,"PHASE4":344,"NA":350},{"trials":337,"activeCount":12},[],{"trials":339,"activeCount":12},[],{"trials":341,"activeCount":12},[],{"trials":343,"activeCount":12},[],{"trials":345,"activeCount":12},[346],{"nctId":322,"briefTitle":323,"status":324,"phases":347,"primaryCompletion":326,"completion":326,"start":327,"enrollment":16,"conditions":348,"interventions":349},[64],[329],[309,331],{"trials":351,"activeCount":12},[],{"intervention":353,"totalTrials":31,"cells":354},"plasma-derived FVIII\u002FVWF concentrate",{"EARLY_PHASE1":355,"PHASE1":357,"PHASE2":359,"PHASE3":361,"PHASE4":363,"NA":375},{"trials":356,"activeCount":12},[],{"trials":358,"activeCount":12},[],{"trials":360,"activeCount":12},[],{"trials":362,"activeCount":12},[],{"trials":364,"activeCount":12},[365],{"nctId":366,"briefTitle":367,"status":368,"phases":369,"primaryCompletion":370,"completion":370,"start":371,"enrollment":12,"conditions":372,"interventions":374},"NCT02472665","Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease","WITHDRAWN",[64],"2024-12-10","2013-12",[373],"Von Willebrand Disease",[353],{"trials":376,"activeCount":12},[],{"intervention":378,"totalTrials":11,"cells":379},"Albumin",{"EARLY_PHASE1":380,"PHASE1":382,"PHASE2":384,"PHASE3":418,"PHASE4":431,"NA":433},{"trials":381,"activeCount":12},[],{"trials":383,"activeCount":12},[],{"trials":385,"activeCount":12},[386,397,408],{"nctId":387,"briefTitle":388,"status":78,"phases":389,"primaryCompletion":390,"completion":390,"start":391,"enrollment":392,"conditions":393,"interventions":395},"NCT00220805","Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration",[62],"2005-05","2004-01",96,[394],"Macular Degeneration",[396,378],"Immune Globulin Intravenous [Human], 10% Caprylate\u002FChromatography Purified",{"nctId":398,"briefTitle":399,"status":78,"phases":400,"primaryCompletion":401,"completion":401,"start":402,"enrollment":403,"conditions":404,"interventions":406},"NCT00220779","Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis",[62],"2005-02","2002-12",128,[405],"Multiple Sclerosis, Relapsing-Remitting",[407,378],"Immune Globulin IV [Human], 10% Caprylate\u002FChromatography Purified",{"nctId":409,"briefTitle":410,"status":78,"phases":411,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":415,"interventions":416},"NCT00263887","Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)",[62],"2007-01","2003-12",77,[21],[417,378],"Alpha1-Proteinase Inhibitor",{"trials":419,"activeCount":12},[420],{"nctId":421,"briefTitle":422,"status":78,"phases":423,"primaryCompletion":424,"completion":424,"start":425,"enrollment":426,"conditions":427,"interventions":429},"NCT00220740","Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",[63],"2006-06","2004-04",117,[428],"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating",[430,378],"Immune Globulin IV (Human), 10% Caprylate\u002FChromatography Purified",{"trials":432,"activeCount":12},[],{"trials":434,"activeCount":12},[],{"intervention":436,"totalTrials":19,"cells":437},"IGIV-C",{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":442,"PHASE3":464,"PHASE4":476,"NA":478},{"trials":439,"activeCount":12},[],{"trials":441,"activeCount":12},[],{"trials":443,"activeCount":12},[444,454],{"nctId":445,"briefTitle":446,"status":78,"phases":447,"primaryCompletion":448,"completion":448,"start":449,"enrollment":450,"conditions":451,"interventions":453},"NCT02473965","Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis",[62],"2019-02","2015-06",60,[452],"Myasthenia Gravis",[436],{"nctId":455,"briefTitle":456,"status":78,"phases":457,"primaryCompletion":458,"completion":458,"start":459,"enrollment":460,"conditions":461,"interventions":463},"NCT02473952","A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis",[62],"2018-01","2015-08",62,[462],"Myasthenia Gravis, Generalized",[436],{"trials":465,"activeCount":12},[466],{"nctId":467,"briefTitle":468,"status":78,"phases":469,"primaryCompletion":470,"completion":470,"start":471,"enrollment":472,"conditions":473,"interventions":475},"NCT02413580","A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations",[63],"2018-04","2015-03",49,[474],"Myasthenia Gravis Exacerbations",[436],{"trials":477,"activeCount":12},[],{"trials":479,"activeCount":12},[],{"intervention":396,"totalTrials":26,"cells":481},{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":492,"PHASE4":507,"NA":509},{"trials":483,"activeCount":12},[],{"trials":485,"activeCount":12},[],{"trials":487,"activeCount":12},[488],{"nctId":387,"briefTitle":388,"status":78,"phases":489,"primaryCompletion":390,"completion":390,"start":391,"enrollment":392,"conditions":490,"interventions":491},[62],[394],[396,378],{"trials":493,"activeCount":12},[494],{"nctId":495,"briefTitle":496,"status":78,"phases":497,"primaryCompletion":498,"completion":499,"start":498,"enrollment":175,"conditions":500,"interventions":505},"NCT00220766","Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients",[63],"2002-08","2004-03",[28,501,502,503,504],"Agammaglobulinemia","Severe Combined Immunodeficiency","Wiskott-Aldrich Syndrome","Common Variable Immunodeficiency",[396,506],"Dextrose, 5% in Water",{"trials":508,"activeCount":12},[],{"trials":510,"activeCount":12},[],{"intervention":111,"totalTrials":26,"cells":512},{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":519,"PHASE4":532,"NA":534},{"trials":514,"activeCount":12},[],{"trials":516,"activeCount":12},[],{"trials":518,"activeCount":12},[],{"trials":520,"activeCount":12},[521,528],{"nctId":522,"briefTitle":523,"status":78,"phases":524,"primaryCompletion":327,"completion":327,"start":424,"enrollment":525,"conditions":526,"interventions":527},"NCT00301366","The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency",[63],38,[21],[111],{"nctId":103,"briefTitle":104,"status":78,"phases":529,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":530,"interventions":531},[63],[21],[44,111],{"trials":533,"activeCount":12},[],{"trials":535,"activeCount":12},[],{"intervention":430,"totalTrials":31,"cells":537},{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":544,"PHASE4":550,"NA":552},{"trials":539,"activeCount":12},[],{"trials":541,"activeCount":12},[],{"trials":543,"activeCount":12},[],{"trials":545,"activeCount":12},[546],{"nctId":421,"briefTitle":422,"status":78,"phases":547,"primaryCompletion":424,"completion":424,"start":425,"enrollment":426,"conditions":548,"interventions":549},[63],[428],[430,378],{"trials":551,"activeCount":12},[],{"trials":553,"activeCount":12},[],{"intervention":259,"totalTrials":31,"cells":555},{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":562,"PHASE4":568,"NA":570},{"trials":557,"activeCount":12},[],{"trials":559,"activeCount":12},[],{"trials":561,"activeCount":12},[],{"trials":563,"activeCount":12},[564],{"nctId":250,"briefTitle":251,"status":78,"phases":565,"primaryCompletion":253,"completion":254,"start":255,"enrollment":256,"conditions":566,"interventions":567},[63],[15],[259,239],{"trials":569,"activeCount":12},[],{"trials":571,"activeCount":12},[],{"intervention":573,"totalTrials":31,"cells":574},"C19-IG 20%",{"EARLY_PHASE1":575,"PHASE1":577,"PHASE2":579,"PHASE3":581,"PHASE4":595,"NA":597},{"trials":576,"activeCount":12},[],{"trials":578,"activeCount":12},[],{"trials":580,"activeCount":12},[],{"trials":582,"activeCount":12},[583],{"nctId":584,"briefTitle":585,"status":324,"phases":586,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":591,"interventions":593},"NCT04847141","A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients",[63],"2021-11-10","2021-12-27","2021-04-28",465,[18,592],"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection",[573,594],"0.9% Sodium chloride",{"trials":596,"activeCount":12},[],{"trials":598,"activeCount":12},[],{"intervention":594,"totalTrials":31,"cells":600},{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":613,"NA":615},{"trials":602,"activeCount":12},[],{"trials":604,"activeCount":12},[],{"trials":606,"activeCount":12},[],{"trials":608,"activeCount":12},[609],{"nctId":584,"briefTitle":585,"status":324,"phases":610,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":611,"interventions":612},[63],[18,592],[573,594],{"trials":614,"activeCount":12},[],{"trials":616,"activeCount":12},[],{"intervention":618,"totalTrials":31,"cells":619},"IGSC 20% daily push versus every 2 weeks pump",{"EARLY_PHASE1":620,"PHASE1":622,"PHASE2":624,"PHASE3":626,"PHASE4":639,"NA":641},{"trials":621,"activeCount":12},[],{"trials":623,"activeCount":12},[],{"trials":625,"activeCount":12},[],{"trials":627,"activeCount":12},[628],{"nctId":629,"briefTitle":630,"status":368,"phases":631,"primaryCompletion":632,"completion":632,"start":633,"enrollment":12,"conditions":634,"interventions":635},"NCT03814798","Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary Immunodeficiency",[63],"2020-09","2019-12",[15],[618,636,637,638],"IGSC 20% daily push versus once a week pump","IGSC 20% daily push versus 2 times per week pump","IGSC 20% 150 mg\u002Fkg",{"trials":640,"activeCount":12},[],{"trials":642,"activeCount":12},[],{"intervention":636,"totalTrials":31,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":651,"PHASE4":657,"NA":659},{"trials":646,"activeCount":12},[],{"trials":648,"activeCount":12},[],{"trials":650,"activeCount":12},[],{"trials":652,"activeCount":12},[653],{"nctId":629,"briefTitle":630,"status":368,"phases":654,"primaryCompletion":632,"completion":632,"start":633,"enrollment":12,"conditions":655,"interventions":656},[63],[15],[618,636,637,638],{"trials":658,"activeCount":12},[],{"trials":660,"activeCount":12},[],{"intervention":637,"totalTrials":31,"cells":662},{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":669,"PHASE4":675,"NA":677},{"trials":664,"activeCount":12},[],{"trials":666,"activeCount":12},[],{"trials":668,"activeCount":12},[],{"trials":670,"activeCount":12},[671],{"nctId":629,"briefTitle":630,"status":368,"phases":672,"primaryCompletion":632,"completion":632,"start":633,"enrollment":12,"conditions":673,"interventions":674},[63],[15],[618,636,637,638],{"trials":676,"activeCount":12},[],{"trials":678,"activeCount":12},[],{"intervention":638,"totalTrials":31,"cells":680},{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":687,"PHASE4":693,"NA":695},{"trials":682,"activeCount":12},[],{"trials":684,"activeCount":12},[],{"trials":686,"activeCount":12},[],{"trials":688,"activeCount":12},[689],{"nctId":629,"briefTitle":630,"status":368,"phases":690,"primaryCompletion":632,"completion":632,"start":633,"enrollment":12,"conditions":691,"interventions":692},[63],[15],[618,636,637,638],{"trials":694,"activeCount":12},[],{"trials":696,"activeCount":12},[],{"intervention":698,"totalTrials":31,"cells":699},"SMT + PE-A 5%",{"EARLY_PHASE1":700,"PHASE1":702,"PHASE2":704,"PHASE3":706,"PHASE4":718,"NA":720},{"trials":701,"activeCount":12},[],{"trials":703,"activeCount":12},[],{"trials":705,"activeCount":12},[],{"trials":707,"activeCount":12},[708],{"nctId":709,"briefTitle":710,"status":324,"phases":711,"primaryCompletion":712,"completion":712,"start":713,"enrollment":714,"conditions":715,"interventions":717},"NCT03702920","Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%",[63],"2025-04-14","2019-02-21",275,[716],"Acute-On-Chronic Liver Failure",[698],{"trials":719,"activeCount":12},[],{"trials":721,"activeCount":12},[],{"intervention":723,"totalTrials":31,"cells":724},"Albutein 20%",{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":731,"PHASE4":743,"NA":745},{"trials":726,"activeCount":12},[],{"trials":728,"activeCount":12},[],{"trials":730,"activeCount":12},[],{"trials":732,"activeCount":12},[733],{"nctId":734,"briefTitle":735,"status":78,"phases":736,"primaryCompletion":737,"completion":737,"start":738,"enrollment":739,"conditions":740,"interventions":742},"NCT03451292","Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites",[63],"2024-05-21","2018-07-24",410,[741],"Decompensated Cirrhosis and Ascites",[723],{"trials":744,"activeCount":12},[],{"trials":746,"activeCount":12},[],{"intervention":748,"totalTrials":31,"cells":749},"Liquid Alpha₁-PI",{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":754,"PHASE3":756,"PHASE4":768,"NA":770},{"trials":751,"activeCount":12},[],{"trials":753,"activeCount":12},[],{"trials":755,"activeCount":12},[],{"trials":757,"activeCount":12},[758],{"nctId":759,"briefTitle":760,"status":78,"phases":761,"primaryCompletion":255,"completion":255,"start":762,"enrollment":763,"conditions":764,"interventions":766},"NCT02282527","A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency",[62,63],"2014-10",32,[765],"Alpha₁-Antitrypsin Deficiency",[748,767],"Prolastin-C",{"trials":769,"activeCount":12},[],{"trials":771,"activeCount":12},[],{"intervention":767,"totalTrials":31,"cells":773},{"EARLY_PHASE1":774,"PHASE1":776,"PHASE2":778,"PHASE3":780,"PHASE4":786,"NA":788},{"trials":775,"activeCount":12},[],{"trials":777,"activeCount":12},[],{"trials":779,"activeCount":12},[],{"trials":781,"activeCount":12},[782],{"nctId":759,"briefTitle":760,"status":78,"phases":783,"primaryCompletion":255,"completion":255,"start":762,"enrollment":763,"conditions":784,"interventions":785},[62,63],[765],[748,767],{"trials":787,"activeCount":12},[],{"trials":789,"activeCount":12},[],{"intervention":194,"totalTrials":31,"cells":791},{"EARLY_PHASE1":792,"PHASE1":794,"PHASE2":796,"PHASE3":798,"PHASE4":804,"NA":806},{"trials":793,"activeCount":12},[],{"trials":795,"activeCount":12},[],{"trials":797,"activeCount":12},[],{"trials":799,"activeCount":12},[800],{"nctId":186,"briefTitle":187,"status":78,"phases":801,"primaryCompletion":189,"completion":189,"start":190,"enrollment":191,"conditions":802,"interventions":803},[63],[15],[54,194],{"trials":805,"activeCount":12},[],{"trials":807,"activeCount":12},[],{"intervention":506,"totalTrials":31,"cells":809},{"EARLY_PHASE1":810,"PHASE1":812,"PHASE2":814,"PHASE3":816,"PHASE4":822,"NA":824},{"trials":811,"activeCount":12},[],{"trials":813,"activeCount":12},[],{"trials":815,"activeCount":12},[],{"trials":817,"activeCount":12},[818],{"nctId":495,"briefTitle":496,"status":78,"phases":819,"primaryCompletion":498,"completion":499,"start":498,"enrollment":175,"conditions":820,"interventions":821},[63],[28,501,502,503,504],[396,506],{"trials":823,"activeCount":12},[],{"trials":825,"activeCount":12},[],{"intervention":827,"totalTrials":26,"cells":828},"Plasmin",{"EARLY_PHASE1":829,"PHASE1":831,"PHASE2":833,"PHASE3":854,"PHASE4":856,"NA":858},{"trials":830,"activeCount":12},[],{"trials":832,"activeCount":12},[],{"trials":834,"activeCount":12},[835,843],{"nctId":836,"briefTitle":837,"status":78,"phases":838,"primaryCompletion":97,"completion":839,"start":840,"enrollment":139,"conditions":841,"interventions":842},"NCT01014975","A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients",[61,62],"2014-02","2009-11",[30],[827,827,827],{"nctId":844,"briefTitle":845,"status":78,"phases":846,"primaryCompletion":847,"completion":255,"start":848,"enrollment":849,"conditions":850,"interventions":852},"NCT01222117","A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion",[62],"2015-12","2010-12",174,[851],"Acute Peripheral Arterial Occlusion",[827,853],"Plasminogen Activator",{"trials":855,"activeCount":12},[],{"trials":857,"activeCount":12},[],{"trials":859,"activeCount":12},[],{"intervention":225,"totalTrials":26,"cells":861},{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":882,"PHASE4":884,"NA":886},{"trials":863,"activeCount":12},[],{"trials":865,"activeCount":12},[],{"trials":867,"activeCount":12},[868,878],{"nctId":869,"briefTitle":870,"status":324,"phases":871,"primaryCompletion":872,"completion":873,"start":874,"enrollment":875,"conditions":876,"interventions":877},"NCT04547140","Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)",[62],"2021-12-13","2022-01-28","2021-01-29",57,[18],[225,178],{"nctId":217,"briefTitle":218,"status":78,"phases":879,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":880,"interventions":881},[61,62],[23],[49,225],{"trials":883,"activeCount":12},[],{"trials":885,"activeCount":12},[],{"trials":887,"activeCount":12},[],{"intervention":178,"totalTrials":26,"cells":889},{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":904,"PHASE4":906,"NA":908},{"trials":891,"activeCount":12},[],{"trials":893,"activeCount":12},[],{"trials":895,"activeCount":12},[896,900],{"nctId":869,"briefTitle":870,"status":324,"phases":897,"primaryCompletion":872,"completion":873,"start":874,"enrollment":875,"conditions":898,"interventions":899},[62],[18],[225,178],{"nctId":169,"briefTitle":170,"status":78,"phases":901,"primaryCompletion":172,"completion":173,"start":174,"enrollment":175,"conditions":902,"interventions":903},[62],[18],[160,178],{"trials":905,"activeCount":12},[],{"trials":907,"activeCount":12},[],{"trials":909,"activeCount":12},[],{"intervention":407,"totalTrials":26,"cells":911},{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":932,"PHASE4":934,"NA":936},{"trials":913,"activeCount":12},[],{"trials":915,"activeCount":12},[],{"trials":917,"activeCount":12},[918,928],{"nctId":919,"briefTitle":920,"status":78,"phases":921,"primaryCompletion":922,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":927},"NCT00220727","Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP",[62],"2003-10","2003-07",8,[926],"Purpura, Thrombocytopenic, Idiopathic",[407],{"nctId":398,"briefTitle":399,"status":78,"phases":929,"primaryCompletion":401,"completion":401,"start":402,"enrollment":403,"conditions":930,"interventions":931},[62],[405],[407,378],{"trials":933,"activeCount":12},[],{"trials":935,"activeCount":12},[],{"trials":937,"activeCount":12},[],{"intervention":417,"totalTrials":26,"cells":939},{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":958,"PHASE4":960,"NA":962},{"trials":941,"activeCount":12},[],{"trials":943,"activeCount":12},[],{"trials":945,"activeCount":12},[946,954],{"nctId":947,"briefTitle":948,"status":78,"phases":949,"primaryCompletion":950,"completion":950,"start":413,"enrollment":951,"conditions":952,"interventions":953},"NCT00486837","Deposition of Inhaled Prolastin in Cystic Fibrosis Patients",[62],"2004-06",72,[25],[417],{"nctId":409,"briefTitle":410,"status":78,"phases":955,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":956,"interventions":957},[62],[21],[417,378],{"trials":959,"activeCount":12},[],{"trials":961,"activeCount":12},[],{"trials":963,"activeCount":12},[],{"intervention":965,"totalTrials":31,"cells":966},"Prolastin-C, 60 mg\u002Fkg",{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":984,"PHASE4":986,"NA":988},{"trials":968,"activeCount":12},[],{"trials":970,"activeCount":12},[],{"trials":972,"activeCount":12},[973],{"nctId":974,"briefTitle":975,"status":78,"phases":976,"primaryCompletion":977,"completion":977,"start":978,"enrollment":979,"conditions":980,"interventions":982},"NCT01213043","Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency",[62],"2012-01","2010-11",30,[33,981],"Alpha 1-antitrypsin Deficiency (AATD)",[965,983],"Prolastin-C, 120 mg\u002Fkg",{"trials":985,"activeCount":12},[],{"trials":987,"activeCount":12},[],{"trials":989,"activeCount":12},[],{"intervention":983,"totalTrials":31,"cells":991},{"EARLY_PHASE1":992,"PHASE1":994,"PHASE2":996,"PHASE3":1002,"PHASE4":1004,"NA":1006},{"trials":993,"activeCount":12},[],{"trials":995,"activeCount":12},[],{"trials":997,"activeCount":12},[998],{"nctId":974,"briefTitle":975,"status":78,"phases":999,"primaryCompletion":977,"completion":977,"start":978,"enrollment":979,"conditions":1000,"interventions":1001},[62],[33,981],[965,983],{"trials":1003,"activeCount":12},[],{"trials":1005,"activeCount":12},[],{"trials":1007,"activeCount":12},[],{"intervention":1009,"totalTrials":31,"cells":1010},"180 mg\u002Fkg Alpha1-PI",{"EARLY_PHASE1":1011,"PHASE1":1013,"PHASE2":1015,"PHASE3":1029,"PHASE4":1031,"NA":1033},{"trials":1012,"activeCount":12},[],{"trials":1014,"activeCount":12},[],{"trials":1016,"activeCount":12},[1017],{"nctId":1018,"briefTitle":1019,"status":324,"phases":1020,"primaryCompletion":1021,"completion":1022,"start":1023,"enrollment":1024,"conditions":1025,"interventions":1027},"NCT02093221","Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus",[62],"2017-01","2017-06","2014-03",76,[1026],"Type 1 Diabetes Mellitus",[1009,1028],"90 mg\u002Fkg Alpha1-PI",{"trials":1030,"activeCount":12},[],{"trials":1032,"activeCount":12},[],{"trials":1034,"activeCount":12},[],{"intervention":1028,"totalTrials":31,"cells":1036},{"EARLY_PHASE1":1037,"PHASE1":1039,"PHASE2":1041,"PHASE3":1047,"PHASE4":1049,"NA":1051},{"trials":1038,"activeCount":12},[],{"trials":1040,"activeCount":12},[],{"trials":1042,"activeCount":12},[1043],{"nctId":1018,"briefTitle":1019,"status":324,"phases":1044,"primaryCompletion":1021,"completion":1022,"start":1023,"enrollment":1024,"conditions":1045,"interventions":1046},[62],[1026],[1009,1028],{"trials":1048,"activeCount":12},[],{"trials":1050,"activeCount":12},[],{"trials":1052,"activeCount":12},[],{"intervention":1054,"totalTrials":31,"cells":1055},"Albutein 5%",{"EARLY_PHASE1":1056,"PHASE1":1058,"PHASE2":1060,"PHASE3":1071,"PHASE4":1073,"NA":1075},{"trials":1057,"activeCount":12},[],{"trials":1059,"activeCount":12},[],{"trials":1061,"activeCount":12},[1062],{"nctId":1063,"briefTitle":1064,"status":78,"phases":1065,"primaryCompletion":1066,"completion":1066,"start":1067,"enrollment":203,"conditions":1068,"interventions":1070},"NCT02872142","Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis",[62],"2019-08-15","2016-08-29",[1069],"Amyotrophic Lateral Sclerosis",[1054],{"trials":1072,"activeCount":12},[],{"trials":1074,"activeCount":12},[],{"trials":1076,"activeCount":12},[],{"intervention":853,"totalTrials":31,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1089,"PHASE4":1091,"NA":1093},{"trials":1080,"activeCount":12},[],{"trials":1082,"activeCount":12},[],{"trials":1084,"activeCount":12},[1085],{"nctId":844,"briefTitle":845,"status":78,"phases":1086,"primaryCompletion":847,"completion":255,"start":848,"enrollment":849,"conditions":1087,"interventions":1088},[62],[851],[827,853],{"trials":1090,"activeCount":12},[],{"trials":1092,"activeCount":12},[],{"trials":1094,"activeCount":12},[],{"intervention":1096,"totalTrials":31,"cells":1097},"Human Plasma-Derived Fibrinogen Concentrate",{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1102,"PHASE3":1113,"PHASE4":1115,"NA":1117},{"trials":1099,"activeCount":12},[],{"trials":1101,"activeCount":12},[],{"trials":1103,"activeCount":12},[1104],{"nctId":1105,"briefTitle":1106,"status":78,"phases":1107,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":108,"conditions":1110,"interventions":1112},"NCT02281500","Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia",[61,62],"2019-11-11","2016-07-22",[1111],"Congenital Afibrinogenemia",[1096],{"trials":1114,"activeCount":12},[],{"trials":1116,"activeCount":12},[],{"trials":1118,"activeCount":12},[],{"intervention":1120,"totalTrials":31,"cells":1121},"Alpha-1 HC 100 mg",{"EARLY_PHASE1":1122,"PHASE1":1124,"PHASE2":1126,"PHASE3":1136,"PHASE4":1138,"NA":1140},{"trials":1123,"activeCount":12},[],{"trials":1125,"activeCount":12},[],{"trials":1127,"activeCount":12},[1128],{"nctId":1129,"briefTitle":1130,"status":78,"phases":1131,"primaryCompletion":201,"completion":201,"start":1132,"enrollment":979,"conditions":1133,"interventions":1134},"NCT01684410","Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis",[62],"2012-08",[25],[1120,1135],"Alpha-1 HC 200 mg",{"trials":1137,"activeCount":12},[],{"trials":1139,"activeCount":12},[],{"trials":1141,"activeCount":12},[],{"intervention":1135,"totalTrials":31,"cells":1143},{"EARLY_PHASE1":1144,"PHASE1":1146,"PHASE2":1148,"PHASE3":1154,"PHASE4":1156,"NA":1158},{"trials":1145,"activeCount":12},[],{"trials":1147,"activeCount":12},[],{"trials":1149,"activeCount":12},[1150],{"nctId":1129,"briefTitle":1130,"status":78,"phases":1151,"primaryCompletion":201,"completion":201,"start":1132,"enrollment":979,"conditions":1152,"interventions":1153},[62],[25],[1120,1135],{"trials":1155,"activeCount":12},[],{"trials":1157,"activeCount":12},[],{"trials":1159,"activeCount":12},[],{"intervention":1161,"totalTrials":31,"cells":1162},"Alphanate",{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1167,"PHASE3":1178,"PHASE4":1180,"NA":1182},{"trials":1164,"activeCount":12},[],{"trials":1166,"activeCount":12},[],{"trials":1168,"activeCount":12},[1169],{"nctId":1170,"briefTitle":1171,"status":324,"phases":1172,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":26,"conditions":1175,"interventions":1177},"NCT03095287","Alphanate in Immune Tolerance Induction Therapy",[62],"2020-09-18","2018-01-03",[1176],"Hemophilia A, Congenital",[1161],{"trials":1179,"activeCount":12},[],{"trials":1181,"activeCount":12},[],{"trials":1183,"activeCount":12},[],{"intervention":1185,"totalTrials":31,"cells":1186},"Immune Globulin Intravenous",{"EARLY_PHASE1":1187,"PHASE1":1189,"PHASE2":1191,"PHASE3":1202,"PHASE4":1204,"NA":1206},{"trials":1188,"activeCount":12},[],{"trials":1190,"activeCount":12},[],{"trials":1192,"activeCount":12},[1193],{"nctId":1194,"briefTitle":1195,"status":78,"phases":1196,"primaryCompletion":1197,"completion":1197,"start":1198,"enrollment":1199,"conditions":1200,"interventions":1201},"NCT00389324","A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency",[62],"2008-08","2006-11",35,[28],[1185],{"trials":1203,"activeCount":12},[],{"trials":1205,"activeCount":12},[],{"trials":1207,"activeCount":12},[],{"intervention":1209,"totalTrials":31,"cells":1210},"AT-III",{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1215,"PHASE3":1228,"PHASE4":1230,"NA":1232},{"trials":1212,"activeCount":12},[],{"trials":1214,"activeCount":12},[],{"trials":1216,"activeCount":12},[1217],{"nctId":1218,"briefTitle":1219,"status":78,"phases":1220,"primaryCompletion":1221,"completion":1221,"start":1222,"enrollment":1223,"conditions":1224,"interventions":1227},"NCT02037555","Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass",[62],"2018-01-25","2014-06-26",425,[1225,1226],"Cardiac Surgery","Cardiopulmonary Bypass",[1209],{"trials":1229,"activeCount":12},[],{"trials":1231,"activeCount":12},[],{"trials":1233,"activeCount":12},[],{"intervention":1235,"totalTrials":31,"cells":1236},"Plasmin (Human) 25 mg",{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1256,"PHASE3":1258,"PHASE4":1260,"NA":1262},{"trials":1238,"activeCount":12},[],{"trials":1240,"activeCount":12},[1241],{"nctId":1242,"briefTitle":1243,"status":78,"phases":1244,"primaryCompletion":1245,"completion":1245,"start":327,"enrollment":1246,"conditions":1247,"interventions":1249},"NCT00418483","A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion",[61],"2010-04",83,[1248],"Arterial Occlusive Diseases",[1235,1250,1251,1252,1253,1254,1255],"Plasmin (Human) 50 mg","Plasmin (Human) 75 mg","Plasmin (Human) 100 mg","Plasmin (Human) 125 mg","Plasmin (Human) 150 mg","Plasmin (Human) 175 mg",{"trials":1257,"activeCount":12},[],{"trials":1259,"activeCount":12},[],{"trials":1261,"activeCount":12},[],{"trials":1263,"activeCount":12},[],{"intervention":1250,"totalTrials":31,"cells":1265},{"EARLY_PHASE1":1266,"PHASE1":1268,"PHASE2":1274,"PHASE3":1276,"PHASE4":1278,"NA":1280},{"trials":1267,"activeCount":12},[],{"trials":1269,"activeCount":12},[1270],{"nctId":1242,"briefTitle":1243,"status":78,"phases":1271,"primaryCompletion":1245,"completion":1245,"start":327,"enrollment":1246,"conditions":1272,"interventions":1273},[61],[1248],[1235,1250,1251,1252,1253,1254,1255],{"trials":1275,"activeCount":12},[],{"trials":1277,"activeCount":12},[],{"trials":1279,"activeCount":12},[],{"trials":1281,"activeCount":12},[],{"intervention":1251,"totalTrials":31,"cells":1283},{"EARLY_PHASE1":1284,"PHASE1":1286,"PHASE2":1292,"PHASE3":1294,"PHASE4":1296,"NA":1298},{"trials":1285,"activeCount":12},[],{"trials":1287,"activeCount":12},[1288],{"nctId":1242,"briefTitle":1243,"status":78,"phases":1289,"primaryCompletion":1245,"completion":1245,"start":327,"enrollment":1246,"conditions":1290,"interventions":1291},[61],[1248],[1235,1250,1251,1252,1253,1254,1255],{"trials":1293,"activeCount":12},[],{"trials":1295,"activeCount":12},[],{"trials":1297,"activeCount":12},[],{"trials":1299,"activeCount":12},[],{"intervention":1252,"totalTrials":31,"cells":1301},{"EARLY_PHASE1":1302,"PHASE1":1304,"PHASE2":1310,"PHASE3":1312,"PHASE4":1314,"NA":1316},{"trials":1303,"activeCount":12},[],{"trials":1305,"activeCount":12},[1306],{"nctId":1242,"briefTitle":1243,"status":78,"phases":1307,"primaryCompletion":1245,"completion":1245,"start":327,"enrollment":1246,"conditions":1308,"interventions":1309},[61],[1248],[1235,1250,1251,1252,1253,1254,1255],{"trials":1311,"activeCount":12},[],{"trials":1313,"activeCount":12},[],{"trials":1315,"activeCount":12},[],{"trials":1317,"activeCount":12},[],{"intervention":1253,"totalTrials":31,"cells":1319},{"EARLY_PHASE1":1320,"PHASE1":1322,"PHASE2":1328,"PHASE3":1330,"PHASE4":1332,"NA":1334},{"trials":1321,"activeCount":12},[],{"trials":1323,"activeCount":12},[1324],{"nctId":1242,"briefTitle":1243,"status":78,"phases":1325,"primaryCompletion":1245,"completion":1245,"start":327,"enrollment":1246,"conditions":1326,"interventions":1327},[61],[1248],[1235,1250,1251,1252,1253,1254,1255],{"trials":1329,"activeCount":12},[],{"trials":1331,"activeCount":12},[],{"trials":1333,"activeCount":12},[],{"trials":1335,"activeCount":12},[],{"intervention":1254,"totalTrials":31,"cells":1337},{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1346,"PHASE3":1348,"PHASE4":1350,"NA":1352},{"trials":1339,"activeCount":12},[],{"trials":1341,"activeCount":12},[1342],{"nctId":1242,"briefTitle":1243,"status":78,"phases":1343,"primaryCompletion":1245,"completion":1245,"start":327,"enrollment":1246,"conditions":1344,"interventions":1345},[61],[1248],[1235,1250,1251,1252,1253,1254,1255],{"trials":1347,"activeCount":12},[],{"trials":1349,"activeCount":12},[],{"trials":1351,"activeCount":12},[],{"trials":1353,"activeCount":12},[],{"intervention":1255,"totalTrials":31,"cells":1355},{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1364,"PHASE3":1366,"PHASE4":1368,"NA":1370},{"trials":1357,"activeCount":12},[],{"trials":1359,"activeCount":12},[1360],{"nctId":1242,"briefTitle":1243,"status":78,"phases":1361,"primaryCompletion":1245,"completion":1245,"start":327,"enrollment":1246,"conditions":1362,"interventions":1363},[61],[1248],[1235,1250,1251,1252,1253,1254,1255],{"trials":1365,"activeCount":12},[],{"trials":1367,"activeCount":12},[],{"trials":1369,"activeCount":12},[],{"trials":1371,"activeCount":12},[],{"intervention":1373,"totalTrials":31,"cells":1374},"RIG-C",{"EARLY_PHASE1":1375,"PHASE1":1377,"PHASE2":1387,"PHASE3":1389,"PHASE4":1391,"NA":1393},{"trials":1376,"activeCount":12},[],{"trials":1378,"activeCount":12},[1379],{"nctId":1380,"briefTitle":1381,"status":78,"phases":1382,"primaryCompletion":1383,"completion":1383,"start":1023,"enrollment":203,"conditions":1384,"interventions":1386},"NCT02139657","An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)",[61],"2014-05",[1385],"Rabies",[1373],{"trials":1388,"activeCount":12},[],{"trials":1390,"activeCount":12},[],{"trials":1392,"activeCount":12},[],{"trials":1394,"activeCount":12},[]]